Related references
Note: Only part of the references are listed.Safety, Tolerability, and Pharmacokinetics of KNS-760704 (Dexpramipexole) in Healthy Adult Subjects
Michael E. Bozik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Toward more efficient clinical trials for amyotrophic lateral sclerosis
Merit E. Cudkowicz et al.
AMYOTROPHIC LATERAL SCLEROSIS (2010)
Clinical significance in the change of decline in ALSFRS-R
Carmen Castrillo-Viguera et al.
AMYOTROPHIC LATERAL SCLEROSIS (2010)
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
Swati P. Aggarwal et al.
LANCET NEUROLOGY (2010)
Mitochondrial dysfunction and intracellular calcium dysregulation in ALS
Hibiki Kawamata et al.
MECHANISMS OF AGEING AND DEVELOPMENT (2010)
Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis
Steve Vucic et al.
CURRENT MOLECULAR MEDICINE (2009)
Amyotrophic lateral sclerosis linked to a novel SOD1 mutation with muscle mitochondrial dysfunction
Stefania Corti et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Amyotrophic lateral sclerosis
Lokesh C. Wijesekera et al.
ORPHANET JOURNAL OF RARE DISEASES (2009)
R(+) pramipexole as a mitochondrially focused neuroprotectant: Initial early phase studies in ALS
Hua Wang et al.
AMYOTROPHIC LATERAL SCLEROSIS (2008)
Design of phase II ALS clinical trials
David A. Schoenfeld et al.
AMYOTROPHIC LATERAL SCLEROSIS (2008)
Scrutinizing enrollment in ALS clinical trials: Room for improvement?
Richard S. Bedlack et al.
AMYOTROPHIC LATERAL SCLEROSIS (2008)
KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis
Valentin K. Gribkoff et al.
CNS NEUROSCIENCE & THERAPEUTICS (2008)
ALSFRS-R score and its ratio: A useful predictor for ALS-progression
Katja Kollewe et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2008)
Designing Clinical Trials in Amyotrophic Lateral Sclerosis
Jeremy M. Shefner
PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA (2008)
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Paul H. Gordon et al.
LANCET NEUROLOGY (2007)
Mitochondrial dysfunction in neurodegenerative disorders
M. Baron et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Phase II/III randomized trial of TCH346 in patients with ALS
R. Miller et al.
NEUROLOGY (2007)
Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial
Petra Kaufmann et al.
AMYOTROPHIC LATERAL SCLEROSIS (2007)
Outcome measures for early phase clinical trials
Paul H. Gordon et al.
AMYOTROPHIC LATERAL SCLEROSIS (2007)
Alternative trial design in amyotrophic lateral sclerosis saves time and patients
Geert Jan Groeneveld et al.
AMYOTROPHIC LATERAL SCLEROSIS (2007)
Selecting promising ALS therapies in clinical trials
Ying Kuen Cheung et al.
NEUROLOGY (2006)
Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS
Paul H. Gordon et al.
NEUROLOGY (2006)
Trial of celecoxib in amyotrophic lateral sclerosis
Merit E. Cudkowicz et al.
ANNALS OF NEUROLOGY (2006)
Mitochondrial dysfunction and amyotrophic lateral sclerosis
I Hervias et al.
MUSCLE & NERVE (2006)
Mitochondrial dysfunction and its role in motor neuron degeneration in ALS
G Manfredi et al.
MITOCHONDRION (2005)
The ALSFRSr predicts survival time in an ALS clinic population
P Kaufmann et al.
NEUROLOGY (2005)
Medical progress: Amyotrophic lateral sclerosis.
LP Rowland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Quality of life in ALS depends on factors other than strength and physical function
Z Simmons et al.
NEUROLOGY (2000)